# Chargeurs

Holding Companies / France

You can continue to receive AlphaValue's Research under MiFID II Learn more

# Robust earnings delivery in more choppy (FX) waters

Earnings/sales releases - 07/09/2018

H1 18 earnings do confirm the ability of Chargeurs' management to deliver in more adverse FX conditions and to stick to its quality growth promises. The up and coming group is no longer a recovery case but an investment proposition offering a steadily-growing cash generation.

## Fact

Chargeurs SA released robust H1 with a bottom line up 10% (see table) which could actually be regarded as very good if FX had not acted as a cold shower. This also translates into modest top-line growth but one should remember that the group is managing to deliver extra growth from an extra high base.

# Chargeurs H1 2018 earnings

€m	H1 2018	H1 2017	Chang	e
Revenue Like-for-like change (%)	287.1	281.8	+5.3	+1.9% <i>+3.1%</i>
EBITDA as a % of revenue	30.6 10.7%	29.1 <i>10.3%</i>	+1.5	+5.2%
Recurring operating profit as a % of revenue	24.8 8.6%	23.5 <i>8.3%</i>	+1.3	+5.5%
Attributable net profit	15.3	13.9	+1.4	+10.1%

## Analysis

Chargeurs' management is rightly arguing that the slowdown in earnings growth is due to: 1) a high recent performance; 2) adverse FX with a US\$ down 12% yoy; and 3) continued capex and opex efforts to deliver long-term profitable growth.

The earnings bridge is cutting a long story short. The FX and continued growth opex have represented a combined €7.3m hit to what would have otherwise been a very respectable 12.3% organic rise in recurring operating earnings. Obviously there is little way to challenge these metrics but the point here is the consistency of the group's communication about these opex efforts.





By business and at the recurring earnings level, H1 can be summarised as a flat contribution from Protective Films (the group's cash-flow machine so far, hit by



#### Pierre-Yves GAUTHIER otherfinancials@alphavalue.eu +33 (0) 1 70 61 10 50 cs.alphavalue.com

AlphaValue is contracted by Chargeurs to provide equity research on Chargeurs , using AlphaValue's unique and transparent methods and procedures. Target price and opinion are thus exclusively determined by those methods and procedures.

Buy	Upside: 40.6%
Target Price (6 months)	€ 30.5
Share Price	€ 21.7
Market Cap. €M	507
Price Momentum	NEGATIVE
Extremes 12Months	21.6 🕨 28.1
Bloomberg	CRI FP Equity
Reuters	CRIP.PA





PERF	1 w	1m	3m	12m
Chargeurs	-13.3%	-9.58%	-9.50%	-7.14%
Other financials	-1.40%	-0.62%	-1.41%	7.26%
STOXX 600	-1.19%	-2.73%	-3.26%	-1.09%

Last updated: 29/06/2018	12/16A	12/17A	12/18E	12/19E
Adjusted P/E (x)	9.79	20.4	16.3	13.2
Dividend yield (%)	5.16	2.70	3.22	3.68
EV/EBITDA(R) (x)	5.07	9.35	9.46	7.83
Adjusted EPS (€)	1.09	1.09	1.33	1.65
Growth in EPS (%)	56.8	0.02	22.2	23.7
Dividend (€)	0.55	0.60	0.70	0.80
Sales (€M)	506	533	567	657
Underlying operat. profit ma	7.68	8.33	8.54	9.11
Attributable net profit (€M)	25.0	25.2	31.0	38.4
ROE (after tax) (%)	11.2	11.0	13.0	14.9
Gearing (%)	-5.43	-2.24	10.6	23.0
Company Val	uation	- <u>Comp</u>	bany Fir	ancials



FX pressure as it is still a net exporter from Europe) which has been substantially offset by an excellent contribution from Fashion Technologies (the ex boring "no-growth" business). This rebalancing is *per se* excellent news as it confirms that the group's expansion strategy is paying attention to a proper balance. The latest acquisition, PCC, is indeed setting Fashion Technologies on course for annual sales of €200m from a current €150m or so. That would set Fashion Technologies at about 2/3rds of Protective Films' size.

While management will not commit to H2 18 as Trump's tweets can disrupt any short-term forecast, it will not be derailed from its investment plans in human talent, acquisitions of businesses related to known ones and productivity as well as capacity investments.

The addition of US-based Main Tape back in H2 16 makes the point. This small unit has been ramped up to group quality targets and can now supply the \$-based markets. It thus closes part of the FX risks that have marred Protective Films over H1.

## Impact

The H1 earnings do not call for any significant adjustment of our model, which had been allowing for this currency hit and continuing opex efforts anyway. The uncertainty hinges more on the speed of integration/leverage from the PCC acquisition that sets the group on a capital-light business model (see update of 29/06/2018). Currency matters are secondary ones.

#### Sales by Geography

**Consolidated P&L Accounts** 

Sales

EBITDA

Change in sales

EBITDA(R) margin

Underlying operating profit Operating profit (EBIT)

of which related to pensions

Adjusted attributable net profit

Actual div. received from equity holdi...

**Cashflow Statement** 

Other operating cash flows

Total operating cash flows

Dividends (parent company)

New shareholders' equity

Change in cash position

Free cash flow (pre div.)

Dividends to minorities interests

No. of shares net of treas. stock (year...

Number of diluted shares (average)

Capital expenditure

Total investment flows

Net interest expense

Total financial flows

Per Share Data

Benchmark EPS

Restated NAV per share

Net dividend per share

Exceptional items & other

Net financial expense

Depreciation

Corporate tax

NOPAT

EBITDA

Paid taxes Exceptional items

Equity associates

Minority interests

Change in WCR

Change in staff costs



Europe (46.0%) Americas (27.0%) Asia (25.0%) Other (2.0%)

12/17A

533

5.25

12.0

54.6

10.6

-10.2

44.4

38.5

-8.50

-4.00

-0.80

0.00

25.2

30.3

54.6

-6.70

0.80

-7.00

-4.30

37.4

-12.9

-17.9

-8.50

-13.8

0.00

7.20

31.3

54.1

16.0

23.3

23.1

1.09

0.60

€M

%

%

€M

%

€M

€M €M

€M

€M

€M

€M

€M

€M

€M

€M

€M

€M

Mio

Mio

€

€ € 12/18E 12/19E

657

15.8

5.85

72.8

11.3

-13.0

59.8

54.8

-9.50

-0.13

-7.46

0.50

0.00

38.4

42.5

72.8

-1.16

0.50

-7.46

-5.00

59.7

-21.0

-31.0

-9.50

-16.3

0.00

0.00

-36.7

-7.97

29.2

23.3

23.3

1.65

0.80

567

6.42

5.91

60.0

10.9

-11.5

48.5

43.5

-9.10

-0.10

-3.84

0.50

0.00

31.0

34.5

60.0

1.26

0.80

-3.84

-5.00

53.2

-26.0

-97.4

-9.10

-14.0

0.00

0.00

-37.3

-81.5

18.1

23.3

23.3

1.33

0.70

#### Valuation Summary

Benchmarks	Value	Weight
NAV/SOTP per share	€ 30.7	55%
Dividend Yield	€ 27.9	20%
DCF	€ 36.6	10%
P/E	€ 35.9	10%
P/Book	€17.1	5%
TARGET PRICE	€ 30.5	100%

Largest comparables

- Ackermans & van H...
- Wacker Chemie
  Akzo Nobel
- AKZO NOD
   Solvav
- Bolloré
- GBL
- Sonae
- Hal Trust

NAV/SOTP Calculation

Balance Sheet		12/17A	12/18E	12/19E
Goodwill	€M	86.2	151	156
Total intangible	€M	88.3	153	158
Tangible fixed assets	€M	63.2	85.0	90.0
Financial fixed assets	€M	11.7	12.0	15.0
WCR	€M	21.1	19.8	21.0
Other assets	€M	24.0	27.0	30.0
Total assets (net of short term liab.)	€M	211	300	318
Ordinary shareholders' equity	€M	230	248	266
Quasi Equity & Preferred	€M			
Minority interests	€M	0.00	0.00	0.00
Provisions for pensions	€M	16.4	14.6	14.8
Other provisions for risks and liabilities	€M	0.70	1.00	1.00
Total provisions for risks and liabilities	€M	17.1	15.6	15.8
Tax liabilities	€M	-30.3	-30.0	-30.0
Other liabilities	€M	3.10	5.00	5.00
Net debt (cash)	€M	-8.90	61.3	61.3
Total liab. and shareholders' equity	€M	211	300	318
Capital Employed				
Capital employed after depreciation	€M	196	282	296
Profits & Risks Ratios				
ROE (after tax)	%	11.0	13.0	14.9
ROCE	%	16.0	12.7	14.8
Gearing (at book value)	%	-2.24	10.6	23.0
Adj. Net debt/EBITDA(R)	x	0.05	1.19	0.98
Interest cover (x)	х	5.07	5.23	6.16
Valuation Ratios				
Reference P/E (benchmark)	x	20.4	16.3	13.2
Free cash flow yield	%	3.09	3.57	5.77
P/Book	х	2.25	2.04	1.90
Dividend yield	%	2.70	3.22	3.68
EV Calculation				
Market cap	€M	518	506	506
+ Provisions	€M	17.1	15.6	15.8
+ Unrecognised acturial losses/(gains)	€M	0.00	0.00	0.00
+ Net debt at year end	€M	-8.90	61.3	61.3
+ Leases debt equivalent	€M	11.9	11.9	11.9
- Financial fixed assets (fair value)	€M	16.0	16.0	16.0
+ Minority interests (fair value)	€M	4.00	4.00	4.00
	€M	526	583	583
= EV	CIVI			
= EV EV/EBITDA(R)	x	9.35	9.46	7.83

Analyst : Pierre-Yves Gauthier, Changes to Forecasts : 29/06/2018.

© 2018, AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by
those methods and procedures. All opinions and estimates included fierein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, we make no representation that it is accurate or complete and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.